15 results on '"Sangara, Rauvynne N."'
Search Results
2. Placenta previa percreta with surrounding organ involvement: a proposal for management.
- Author
-
Koji Matsuo, Sangara, Rauvynne N., Shinya Matsuzaki, Ouzounian, Joseph G., Hanks, Sue E., Kazuhide Matsushima, Amaya, Rodolfo, Roman, Lynda D., and Wright, Jason D.
- Published
- 2023
- Full Text
- View/download PDF
3. Pregnancy characteristics and outcomes after bariatric surgery: national-level analysis in the United States.
- Author
-
Youssefzadeh, Ariane C., Klar, Maximilian, Seifert, Gabriel J., Mandelbaum, Rachel S., Sangara, Rauvynne N., McCarthy, Lauren E., Cheng, Vincent, Matsushima, Kazuhide, Ouzounian, Joseph G., and Matsuo, Koji
- Abstract
Bariatric surgery is an effective surgical treatment for weight reduction in individuals with obesity. Pregnancy outcomes related to prior bariatric surgery are currently under active investigation. To assess national-level trends, characteristics, and outcomes of pregnancy after bariatric surgery in the United States. Retrospective cohort study queried the National Inpatient Sample. The study population was 14,648,135 patients who had vaginal or cesarean delivery from January 2016 to December 2019. Exposure allocation was based on the history of bariatric surgery. The main outcomes were (1) trends and characteristics related to bariatric surgery, assessed with multivariable binary logistic regression model; and (2) Centers for Disease Control and Prevention–defined severe maternal morbidity, assessed by propensity score matching and generalized estimating equation. A total of 53,950 (.4%) patients had prior bariatric surgery. The number of patients with prior bariatric surgery increased from.3% to.5%, and this trend remained independent in multivariable analysis (P <.001). Patients who had bariatric surgery were also more likely to be older and have obesity, medical co-morbidities, fetal growth restriction, preterm birth, and cesarean delivery compared with those without bariatric surgery (all, P <.05). In a propensity score matched model, patients who had bariatric surgery were more likely to receive blood product transfusion (2.3% versus 1.6%; odds ratio = 1.45; 95% confidence interval, 1.19–1.77), but severe maternal morbidity other than blood product transfusion was comparable to those without (1.1% versus 1.4%; odds ratio =.80; 95% confidence interval,.63–1.02). There is a gradual increase of pregnancy after bariatric surgery in recent years in the United States. 1. This national-level analysis examined 14.6-million pregnancies from 2016-2019 2. Number of pregnancies after bariatric surgery increased from 0.3% to 0.5% 3. Bariatric surgery was associated with high-risk pregnancy characteristics 4. Bariatric surgery was not associated with non-transfusion severe maternal morbidity [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Gynecologic oncologists in surgery for placenta accreta spectrum: a survey for practice, experience, and interest.
- Author
-
Koji Matsuo, Vestal, Nicole L., Rau, Alesandra R., Sangara, Rauvynne N., Youssefzadeh, Ariane C., Bainvoll, Liat, Matsuzaki, Shinya, Roman, Lynda D., Ouzounian, Joseph G., and Wright, Jason D.
- Published
- 2022
- Full Text
- View/download PDF
5. Trends, Characteristics, and Outcomes of Placenta Accreta Spectrum: A National Study in the United States
- Author
-
Matsuzaki, Shinya, Mandelbaum, Rachel S., Sangara, Rauvynne N., McCarthy, Lauren E., Vestal, Nicole L., Klar, Maximilian, Matsushima, Kazuhide, Amaya, Rodolfo, Ouzounian, Joseph G., and Matsuo, Koji
- Abstract
(Abstracted from Am J Obstet Gynecol2021;225:534.e1–534.e38)Placenta accreta spectrum (PAS) describes the phenomenon wherein the trophoblastic placental tissue morbidly attaches to the myometrium of the gravid uterus, preventing normal detachment and causing morbidity. Depending on the degree of invasion, PAS is categorized as accreta if attached to the myometrium without decidua, increta if invasion occurs into the myometrium, and percreta if invasion through the myometrium into surrounding organs occurs.
- Published
- 2022
- Full Text
- View/download PDF
6. 922 Temporal, regional and hospital-type variation in EMTALA violations involving obstetric emergencies, 2018-2023.
- Author
-
Ahmed, Sameer, Sangara, Rauvynne N., Toomer, Carmen, Sison, Olivia, Reichert, Zach, Nguyen, Brian, Menchine, Michael, Seabury, Seth A., Terp, Sophie, and Axeen, Sarah
- Subjects
OBSTETRICAL emergencies - Published
- 2024
- Full Text
- View/download PDF
7. 860 Increasing postpartum hemorrhage and blood product transfusion at delivery in the United States, 2016-2020.
- Author
-
Sangara, Rauvynne N., Faulkner, Shakeela, Komatsu, Emi, Matsushima, Kazuhide, Mandelbaum, Rachel S., Grubbs, Brendan, Incerpi, Marc H., Ouzounian, Joseph G., and Matsuo, Koji
- Subjects
POSTPARTUM hemorrhage ,BLOOD transfusion ,BLOOD products ,DELIVERY (Obstetrics) - Published
- 2024
- Full Text
- View/download PDF
8. Decreasing Failure-to-Rescue From Severe Maternal Morbidity at Cesarean Delivery: Recent US Trends
- Author
-
Matsuo, Koji, Mandelbaum, Rachel S., Matsuzaki, Shinya, Sangara, Rauvynne N., Lee, Richard H., Klar, Maximilian, and Ouzounian, Joseph G.
- Published
- 2021
- Full Text
- View/download PDF
9. 946 Fetal blood gases after in utero carbon dioxide insufflation for percutaneous fetoscopic spina bifida repair.
- Author
-
Sangara, Rauvynne N., Chon, Andrew H., Van Speybroeck, Alexander, Chu, Jason, Llanes, Arlyn, Kontopoulos, Eftichia V., Quintero, Ruben A., and Chmait, Ramen H.
- Subjects
INSUFFLATION ,CORD blood ,BLOOD gases ,SPINA bifida ,CARBON dioxide ,UMBILICAL veins - Published
- 2021
- Full Text
- View/download PDF
10. Decreasing trends of elective cesarean delivery in the United States.
- Author
-
Youssefzadeh, Ariane C., Sangara, Rauvynne N., Mandelbaum, Rachel S., Matsushima, Kazuhide, Klar, Maximilian, Ouzounian, Joseph G., and Matsuo, Koji
- Subjects
CESAREAN section - Published
- 2022
- Full Text
- View/download PDF
11. Cesarean delivery after bariatric surgery: trends and outcomes in the United States.
- Author
-
Youssefzadeh, Ariane C., Klar, Maximilian, Sangara, Rauvynne N., Matsushima, Kazuhide, Mandelbaum, Rachel S., Ouzounian, Joseph G., and Matsuo, Koji
- Subjects
CESAREAN section ,BARIATRIC surgery ,TREATMENT effectiveness - Published
- 2022
- Full Text
- View/download PDF
12. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States.
- Author
-
Matsuzaki, Shinya, Mandelbaum, Rachel S., Sangara, Rauvynne N., McCarthy, Lauren E., Vestal, Nicole L., Klar, Maximilian, Matsushima, Kazuhide, Amaya, Rodolfo, Ouzounian, Joseph G., and Matsuo, Koji
- Subjects
PLACENTA praevia ,PLACENTA accreta ,CESAREAN section ,HOSPITAL size ,REPRODUCTIVE technology ,GENERALIZED estimating equations ,BREECH delivery ,DATABASES ,LENGTH of stay in hospitals ,RESEARCH ,POSTPARTUM hemorrhage ,HYSTERECTOMY ,ACADEMIC medical centers ,HOSPITAL utilization ,AGE distribution ,MULTIVARIATE analysis ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,HOSPITAL mortality ,URBAN hospitals ,URINARY organs ,COMPARATIVE studies ,PARITY (Obstetrics) ,HUMAN reproductive technology ,BLOOD coagulation disorders ,COMORBIDITY ,TOBACCO ,ECONOMICS - Abstract
Background: Although an infrequent occurrence, the placenta can adhere abnormally to the gravid uterus leading to significantly high maternal morbidity and mortality during cesarean delivery. Contemporary national statistics related to a morbidly adherent placenta, referred to as placenta accreta spectrum, are needed.Objective: This study aimed to examine national trends, characteristics, and perioperative outcomes of women who underwent cesarean delivery for placenta accreta spectrum in the United States.Study Design: This is a population-based retrospective, observational study querying the National Inpatient Sample. The study cohort included women who underwent cesarean delivery from October 2015 to December 2017 and had a diagnosis of placenta accreta spectrum. The main outcome measures were patient characteristics and surgical outcomes related to placenta accreta spectrum assessed by the generalized estimating equation on multivariable analysis. The temporal trend of placenta accreta spectrum was also assessed by linear segmented regression with log transformation.Results: Of 2,727,477 cases who underwent cesarean delivery during the study period, 8030 (0.29%) had the diagnosis of placenta accreta spectrum. Placenta accreta was the most common diagnosis (n=6205, 0.23%), followed by percreta (n=1060, 0.04%) and increta (n=765, 0.03%). The number of placenta accreta spectrum cases increased by 2.1% every quarter year from 0.27% to 0.32% (P=.004). On multivariable analysis, (1) patient demographics (older age, tobacco use, recent diagnosis, higher comorbidity, and use of assisted reproductive technology), (2) pregnancy characteristics (placenta previa, previous cesarean delivery, breech presentation, and grand multiparity), and (3) hospital factors (urban teaching center and large bed capacity hospital) represented the independent characteristics related to placenta accreta spectrum (all, P<.05). The median gestational age at cesarean delivery was 36 weeks for placenta accreta and 34 weeks for both placenta increta and percreta vs 39 weeks for non-placenta accreta spectrum cases (P<.001). On multivariable analysis, cesarean delivery complicated by placenta accreta spectrum was associated with increased risk of any surgical morbidities (78.3% vs 10.6%), Centers for Disease Control and Prevention-defined severe maternal morbidity (60.3% vs 3.1%), hemorrhage (54.1% vs 3.9%), coagulopathy (5.3% vs 0.3%), shock (5.0% vs 0.1%), urinary tract injury (8.3% vs 0.2%), and death (0.25% vs 0.01%) compared with cesarean delivery without placenta accreta spectrum. When further analyzed by subtype, cesarean delivery for placenta increta and percreta was associated with higher likelihood of hysterectomy (0.4% for non-placenta accreta spectrum, 45.8% for accreta, 82.4% for increta, 78.3% for percreta; P<.001) and urinary tract injury (0.2% for non-placenta accreta spectrum, 5.2% for accreta, 11.8% for increta, 24.5% for percreta; P<.001). Moreover, women in the placenta increta and percreta groups had markedly increased risks of surgical mortality compared with those without placenta accreta spectrum (increta, odds ratio, 19.9; and percreta, odds ratio, 32.1).Conclusion: Patient characteristics and outcomes differ across the placenta accreta spectrum subtypes, and women with placenta increta and percreta have considerably high surgical morbidity and mortality risks. Notably, 1 in 313 women undergoing cesarean delivery had a diagnosis of placenta accreta spectrum by the end of 2017, and the incidence seems to be higher than reported in previous studies. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States.
- Author
-
Mandelbaum, Rachel S., Matsuzaki, Shinya, Sangara, Rauvynne N., Klar, Maximilian, Matsushima, Kazuhide, Roman, Lynda D., Paulson, Richard J., Wright, Jason D., and Matsuo, Koji
- Subjects
SALPINGECTOMY ,CESAREAN section ,TUBAL sterilization ,OVARIAN cancer ,GYNECOLOGIC surgery ,STERILIZATION of women ,GENERALIZED estimating equations ,RESEARCH ,OVARIAN tumors ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies - Abstract
Background: Opportunistic salpingectomy is now recommended at the time of routine gynecologic surgery to reduce the risk of future ovarian cancer, and performance of opportunistic salpingectomy has increased markedly at the time of benign hysterectomy. Salpingectomy has also been suggested to be feasible at the time of cesarean delivery in women desiring sterilization; however, uptake has not been previously studied on a national level.Objective: This study aimed to examine recent population trends in the utilization and characteristics of salpingectomy at the time of cesarean delivery in the United States.Study Design: This is a population-based retrospective observational study querying the National Inpatient Sample between October 2015 and December 2018. The primary outcome measure was the temporal trend of bilateral salpingectomy at cesarean delivery, assessed with linear segmented regression with log transformation utilizing 3-month time increments. The secondary outcome measures included patient characteristics associated with bilateral salpingectomy, assessed with a multinomial regression model, and surgical outcome (hemorrhage, blood transfusion, hysterectomy, and oophorectomy) at the time of bilateral salpingectomy vs bilateral tubal ligation, assessed with generalized estimating equation in a propensity score-matched model.Results: There were 3,813,823 women at the age of 15 to 49 years who had cesarean deliveries included, of whom 397,260 (10.4%) had bilateral salpingectomy and 203,400 (5.3%) had bilateral tubal ligation overall. During the time period studied, performance of bilateral salpingectomy among women undergoing cesarean delivery significantly increased from 4.6% to 13.2% (odds ratio for the fourth quarter of 2018 vs the fourth quarter of 2015, 2.69; 95% confidence interval, 2.63-2.75; Figure panel). In contrast, performance of bilateral tubal ligation among women undergoing cesarean delivery significantly decreased from 11.3% to 2.4% (odds ratio, 0.20; 95% confidence interval, 0.19-0.21). By the third quarter of 2016, the number of women who had bilateral salpingectomy exceeded those who had bilateral tubal ligation at cesarean delivery (8.6% vs 7.3%). Increasing the utilization of bilateral salpingectomy did not vary across age groups; the salpingectomy rate increased from 7.5% to 21.1% among women at the age of ≥35 years and from 3.8% to 10.7% among women at the age of <35 years (both, P<.001). In a propensity score matched model, women in the bilateral salpingectomy group were more likely to have hemorrhage (3.8% vs 3.1%; odds ratio, 1.24; 95% confidence interval, 1.15-1.33), blood product transfusion (2.1% vs 1.8%; odds ratio, 1.16; 95% confidence interval, 1.04-1.30), hysterectomy (0.8% vs 0.4%; odds ratio, 2.28; 95% confidence interval, 1.84-2.82), and oophorectomy (0.3% vs 0.2%; odds ratio, 2.02; 95% confidence interval, 1.47-2.79) than those in the bilateral tubal ligation group. When restricted to the nonhysterectomy cases, the bilateral salpingectomy group had a higher rate of hemorrhage (3.4% vs 3.0%; odds ratio, 1.16; 95% confidence interval, 1.06-1.26) and oophorectomy (0.3% vs 0.1%; odds ratio, 1.75; 95% confidence interval, 1.22-2.50) than the bilateral tubal ligation group.Conclusion: In the United States, the utilization of bilateral salpingectomy at the time of cesarean delivery increased rapidly between 2015 and 2018, replacing tubal ligation as the most common type of sterilization performed with cesarean delivery. The higher surgical morbidity in the bilateral salpingectomy group than the bilateral tubal ligation group observed in this study warrants further investigation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
- Author
-
Toze, Cynthia L., Sangara, Rauvynne N, Connors, Joseph M., Nevill, Thomas J., Shepherd, John D., Lavoie, Julye, Barnett, Michael J, Nantel, Stephen H., Voss, Nicholas, Hogge, Donna E., Sutherland, Heather J., Forrest, Donna L, Song, Kevin W, Mourad, Yasser Abou, Power, Maryse M, Narayanan, Sujaatha, Brinkman, Ryan, and Smith, Clayton
- Abstract
Chronic lymphocytic leukemia, a disease that is not curable with standard therapy, is an attractive target for allogeneic (allo) hematopoetic stem cell transplant (HSCT) with demonstrated strong graft vs. leukemia effect. However, optimal selection of patients (pts) in order to maximize outcome and minimize toxicity is still under study. We hypothesized that patient co morbidity, as measured by the HSCT adapted Charlson co morbidity index (CCI) would have a strong effect in this group of patients with older median age. At the Leukemia/BMT Program of BC the CCI has been prospectively calculated for HSCT pts since 2006, and we performed chart review to calculate scores retrospectively for the remaining CLL allo HSCT patients in order to evaluate the impact of this factor on outcome following allo HSCT. Transplant specific data was collected prospectively and entered into an electronic database. Forty pts with CLL proceeded to allo HSCT between Jan 91 and Dec 07, with myeloablative (MA) (n=21) or non-myeloablative/reduced-intensity (NMA/RIC) (n=12/7) conditioning regimen. Median (range) number of prior therapies was 4 (1–7). Twenty-four pts were refractory to fludarabine. Donors were related in 25 cases, unrelated in 15. Median age (range) was 49 yrs (32–57) (MA) and 57 yrs (52–64) (NMA/RIC), with 3 and 13 patients greater than age 55 in the 2 groups respectively. Interval from dx to HSCT was 60 months (range 7–135) (MA) and 90 months (range 18–350) (NMA/RIC). Five yr OS is 55% for the whole group; 51% for the MA group at a median follow-up (med FU) of 7.2 yrs (range 2.8–14.6) and 62% for the NMA/RIC group with med FU of 4.2 yrs (range 0.1–6.8). OS did not differ between the 2 groups (p=0.56). Related and unrelated donors had similar 5yr OS at 60.6 vs. 47.1%, p=0.23. Cumulative incidence of non-relapse mortality at 100 days and 2 years is 10 and 32% for the whole group, 14 and 38% for the MA and 6 and 26% for the NMA/RIC groups. CCI was 0, 1, 2, and 3 or greater for 21, 5, 7, and 7 patients. OS by CCI 0–2 vs. >=3 was 63 vs.18% for the whole group (p=0.01), 56 vs. 0% for the MA (p=0.03), and 74 vs. 27% for the NMA/RIC groups (p=0.06). Further analyses will explore the relationship between CCI and NRM, acute and chronic graft vs. host disease, and relapse. Patient numbers in this series are insufficient to evaluate the impact of specific co morbidities. In conclusion, for patients with CLL, who are in general of older age, and who may have other therapeutic options, allo SCT is optimally performed in those with a low co morbidity score. Patients with a CCI of 3 or greater may be preferential candidates for alternate less toxic therapies.
- Published
- 2008
- Full Text
- View/download PDF
15. Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
- Author
-
Toze, Cynthia L., Sangara, Rauvynne N, Connors, Joseph M., Nevill, Thomas J., Shepherd, John D., Lavoie, Julye, Barnett, Michael J, Nantel, Stephen H., Voss, Nicholas, Hogge, Donna E., Sutherland, Heather J., Forrest, Donna L, Song, Kevin W, Mourad, Yasser Abou, Power, Maryse M, Narayanan, Sujaatha, Brinkman, Ryan, and Smith, Clayton
- Abstract
Chronic lymphocytic leukemia, a disease that is not curable with standard therapy, is an attractive target for allogeneic (allo) hematopoetic stem cell transplant (HSCT) with demonstrated strong graft vs. leukemia effect. However, optimal selection of patients (pts) in order to maximize outcome and minimize toxicity is still under study. We hypothesized that patient co morbidity, as measured by the HSCT adapted Charlson co morbidity index (CCI) would have a strong effect in this group of patients with older median age. At the Leukemia/BMT Program of BC the CCI has been prospectively calculated for HSCT pts since 2006, and we performed chart review to calculate scores retrospectively for the remaining CLL allo HSCT patients in order to evaluate the impact of this factor on outcome following allo HSCT. Transplant specific data was collected prospectively and entered into an electronic database. Forty pts with CLL proceeded to allo HSCT between Jan 91 and Dec 07, with myeloablative (MA) (n=21) or non-myeloablative/reduced-intensity (NMA/RIC) (n=12/7) conditioning regimen. Median (range) number of prior therapies was 4 (1–7). Twenty-four pts were refractory to fludarabine. Donors were related in 25 cases, unrelated in 15. Median age (range) was 49 yrs (32–57) (MA) and 57 yrs (52–64) (NMA/RIC), with 3 and 13 patients greater than age 55 in the 2 groups respectively. Interval from dx to HSCT was 60 months (range 7–135) (MA) and 90 months (range 18–350) (NMA/RIC). Five yr OS is 55% for the whole group; 51% for the MA group at a median follow-up (med FU) of 7.2 yrs (range 2.8–14.6) and 62% for the NMA/RIC group with med FU of 4.2 yrs (range 0.1–6.8). OS did not differ between the 2 groups (p=0.56). Related and unrelated donors had similar 5yr OS at 60.6 vs. 47.1%, p=0.23. Cumulative incidence of non-relapse mortality at 100 days and 2 years is 10 and 32% for the whole group, 14 and 38% for the MA and 6 and 26% for the NMA/RIC groups. CCI was 0, 1, 2, and 3 or greater for 21, 5, 7, and 7 patients. OS by CCI 0–2 vs. >=3 was 63 vs.18% for the whole group (p=0.01), 56 vs. 0% for the MA (p=0.03), and 74 vs. 27% for the NMA/RIC groups (p=0.06). Further analyses will explore the relationship between CCI and NRM, acute and chronic graft vs. host disease, and relapse. Patient numbers in this series are insufficient to evaluate the impact of specific co morbidities. In conclusion, for patients with CLL, who are in general of older age, and who may have other therapeutic options, allo SCT is optimally performed in those with a low co morbidity score. Patients with a CCI of 3 or greater may be preferential candidates for alternate less toxic therapies.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.